Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Clinical trial NCT04547946 · COMPLETED

Trial details

NCT number: NCT04547946
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Study type: OBSERVATIONAL

Malignant Melanoma

Start date: 2021-10-15
Primary completion: 2022-06-07
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.